Accessibility Menu
Sab Biotherapeutics logo

Sab Biotherapeutics

(NASDAQ) SABSW

Current Price$0.01
Market CapN/A
Since IPO (2021)-99%
5 Year-98%
1 Year-68%
1 Month-51%

Sab Biotherapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$398.43K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Price

$0.01

Volume

0

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.18

Estimated Earnings Date

Aug 6, 2026

SABSW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sab Biotherapeutics

Industry

Biotechnology

Headquarters

Sioux Falls, SD 33140, US

SABSW Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

-24%

Return on Assets

-0%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

0

Volume

0

Avg. Volume

18.43K

Financials (TTM)

Gross Profit

-$3.08M

Operating Income

-$48.95M

EBITDA

$16.60M

Operating Cash Flow

-$44.78M

Capital Expenditure

-$933.15K

Free Cash Flow

-$45.71M

Cash & ST Invst.

$96.59M

Total Debt

$5.95M

Sab Biotherapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$752.67K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

63

N/A

Net Income

-$18.87M

-263.1%

EBITDA

-$19.25M

-342.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$101.22M

+1568.2%

Accounts Receivable

$1.56M

+7171.4%

Inventory

$0.00

N/A

Long Term Debt

$5.25M

-7.9%

Short Term Debt

$920.66K

-14.5%

Return on Assets

-0.16%

N/A

Return on Invested Capital

-24.38%

N/A

Free Cash Flow

-$15.25M

-95.6%

Operating Cash Flow

-$14.27M

-83.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VINCVincerx Pharma, Inc.
$0.01+4.10%
BACKIMAC Holdings, Inc.
$0.04+0.00%
BCTXWBriaCell Therapeutics Corp.
$0.00-0.00%
SYRSSyros Pharmaceuticals, Inc.
$0.00+100.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About SABSW

What is the current price of Sab Biotherapeutics?

Sab Biotherapeutics is trading at $0.01 per share.

What is the 52-week range for Sab Biotherapeutics?

Over the past 52 weeks, Sab Biotherapeutics has traded between $0.01 and $0.18.

How much debt does Sab Biotherapeutics have?

Sab Biotherapeutics total debt is unavailable.

How much cash does Sab Biotherapeutics have on hand?

Sab Biotherapeutics does not have cash on hand data available.

What is Sab Biotherapeutics’s dividend yield?

Sab Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.